Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 31, 2010

BTG to Facilitate Return of U.S. Drug Rights from Nycomed with up to $16.6M

  • BTG will pay Nycomed up to $16.6 million as part of an agreement designed to streamline transfer of the latter’s exclusive U.S. distribution rights to the rattlesnake antivenom CroFab™ and the digoxin-overdose antidote DigiFab™ back to BTG. Nycomed’s contractual rights to the drugs are due to end on September 30, although under terms of this contract the company has rights to sell remaining inventories for up to a further six months.

    The new agreement means the firms will cooperate on the transition of sales, marketing, promotion, and distribution activities back to BTG, which will also have access to Nycomed’s market data, customers, and sales force. From October 1 BTG will have exclusive rights to market and sell the products. The total payment due to Nycomed will depend on the amount of product delivered to and sold by the firm before September 30. BTG says it expects the final payment will be in the region of $14.5 million.

    CroFab is marketed by Swedish Orphan International in the Nordic countries; and by BTG in other EU countries and the rest of the world. Beacon Pharmaceuticals markets DigiFab in the EU (excluding the Nordic countries). BTG and local partners market the drug in the rest of the world.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »